Shinnosuke Takemoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7359204/publications.pdf

Version: 2024-02-01

1937685 1720034 10 52 4 7 citations g-index h-index papers 12 12 12 51 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. Supportive Care in Cancer, 2016, 24, 615-619.	2.2	14
2	Remarkable response to pembrolizumab with platinumâ€doublet in PD‣1â€low pulmonary sarcomatoid carcinoma: A case report. Thoracic Cancer, 2021, 12, 1126-1130.	1.9	11
3	Phase II trial of a nonâ€platinum triplet for patients with advanced nonâ€small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. Thoracic Cancer, 2019, 10, 452-458.	1.9	8
4	Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase <scp>II</scp> study. Thoracic Cancer, 2020, 11, 1972-1978.	1.9	4
5	Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor. Journal of Clinical Medicine, 2021, 10, 4221.	2.4	4
6	Phase I/II Study of Amrubicin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer. Chemotherapy, 2014, 60, 180-184.	1.6	3
7	Phase II study of nedaplatin and amrubicin as firstâ€line treatment for advanced squamous cell lung cancer. Thoracic Cancer, 2019, 10, 1764-1769.	1.9	3
8	Phase II study of ramucirumab and docetaxel for previously treated nonâ€small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. Thoracic Cancer, 2020, 11, 389-393.	1.9	3
9	Efficacy of Sâ€1 after pemetrexed in patients with nonâ€small cell lung cancer: A retrospective multiâ€institutional analysis. Thoracic Cancer, 2021, 12, 2300-2306.	1.9	1
10	A Case of Advanced Thymic Carcinoma in Which Carboplatin and Nab-paclitaxel Were Significantly Effective After Progression on Lenvatinib. Japanese Journal of Lung Cancer, 2022, 62, 115-120.	0.1	1